You are here

Article info

Article menu
Chronic obstructive pulmonary disease
Efficacy of a new once-daily long-acting inhaled β2-agonist indacaterol versus twice-daily formoterol in COPD
Free

Authors

  1. Correspondence to Professor R Dahl, Department of Respiratory Diseases, Aarhus University Hospital, Aarhus, Denmark; ronadahl{at}rm.dk
View Full Text

Citation

Dahl R, Chung KF, Buhl R, et al
Efficacy of a new once-daily long-acting inhaled β2-agonist indacaterol versus twice-daily formoterol in COPD
Thorax 2010;65:473-479.

Publication history

  • Received August 19, 2009
  • Accepted March 23, 2010
  • First published June 3, 2010.
Online issue publication 
September 01, 2022

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Copyright information

© 2010, Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions.